The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| COO | -20.9% | -9.66% | -2.01% | +1,043% |
| S&P | +13.01% | +86.49% | +13.27% | +4,022% |
The Cooper Cos, Inc. operates as a medical device company. It operates through the Cooper Vision and Cooper Surgical segments. The Cooper Vision segment develops, manufactures, and markets products for contact lens wearers, which solves vision challenges such as astigmatism, presbyopia, myopia, ocular dryness, and eye fatigues. The Cooper Surgical segment focuses on the provision of advancement for the health of women, babies, and families through women's health and fertility products and services. The company was founded in 1958 and is headquartered in San Ramon, CA.
Sometimes it takes more than an earnings beat to make the market happy about a company.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $1.07B | 4.6% |
| Gross Profit | $601.00M | -4.2% |
| Gross Margin | 56.42% | -5.2% |
| Market Cap | $13.90B | -33.3% |
| Market Cap / Employee | $0.93M | 0.0% |
| Employees | 15K | -6.2% |
| Net Income | $84.60M | -28.0% |
| EBITDA | $238.80M | -17.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $110.60M | 2.7% |
| Accounts Receivable | $829.00M | 15.6% |
| Inventory | 846 | 5.4% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $2.70B | -3.0% |
| Short Term Debt | $85.60M | 19.1% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 3.03% | -0.2% |
| Return On Invested Capital | 9.84% | -1.2% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $149.90M | 17.0% |
| Operating Free Cash Flow | $247.90M | -7.5% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 46.69 | 39.61 | 34.80 | 37.31 | -30.30% |
| Price to Book | 2.38 | 2.01 | 1.70 | 1.66 | -36.73% |
| Price to Sales | 4.94 | 4.11 | 3.49 | 3.38 | -37.38% |
| Price to Tangible Book Value | 7.85 | 6.29 | 5.17 | 4.87 | -44.86% |
| Price to Free Cash Flow TTM | 50.50 | 44.80 | 34.32 | 31.93 | -56.30% |
| Enterprise Value to EBITDA | 80.09 | 67.99 | 60.83 | 69.19 | -15.86% |
| Free Cash Flow Yield | 2.0% | 2.2% | 2.9% | 3.1% | 128.82% |
| Return on Equity | 5.3% | 5.1% | 5.0% | 4.6% | -8.46% |
| Total Debt | $2.54B | $2.59B | $2.48B | $2.78B | -2.44% |
No podcast episodes available.
COO earnings call for the period ending June 30, 2022.
COO earnings call for the period ending March 31, 2022.
COO earnings call for the period ending December 31, 2021.
COO earnings call for the period ending September 30, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
